CDMO Avid Bioservices, Inc Earnings per share for the last twelve months

Corporate company logo of Avid Bioservices (CDMO)

Avid Bioservices, Inc. (CDMO) relies heavily on external reagent suppliers while implementing automation to eliminate biosynthesis errors. The annual net income per share illustrates the long-term business trend, where -2.40 represents the current metric level. Stability is ensured by long-term contracts for the production of biologics at the company's own high-tech plants in California.

Avid Bioservices, Inc. (CDMO) - Earnings per share for the last four quarters from 07/04/2022 to 02/16/2025

Summary analytical data breakdowns for Avid Bioservices, Inc. (CDMO)

- stock price and consensus target price:
Fundamental company valuation:Avid Bioservices Inc. (CDMO)
Manufactured products of Avid Bioservices Inc

Avid Bioservices, Inc. (CDMO) is scaling its biologic production capacities for the global pharmaceutical market. The rolling year earnings per share trend reflects the efficiency of this expansion. This metric is calculated as the ratio of net profit to the total number of securities, excluding the impact of issuance. The growth of this indicator confirms the successful ramp-up of plants to design capacity and increasing margins. This positive trend signals the business's ability to convert capital expenditures into real shareholder returns.